Evidence map›Paper›PMID 24086739›Full record

ArticlePloS one2013

A novel MAPT mutation, G55R, in a frontotemporal dementia patient leads to altered Tau function.

Abhinaya Iyer, Nichole E Lapointe, Krzysztof Zielke, Mariusz Berdynski, Elmer Guzman, Anna Barczak, Małgorzata Chodakowska-Żebrowska, Maria Barcikowska, Stuart Feinstein, Cezary Zekanowski

Open access · goldAbstract readCase Reports
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Disentangling tau: One protein, many therapeutic approaches.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Review
  2. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.International journal of molecular sciences · 2022
    Review
  3. Article
  4. Review
  5. MAPT mutations, tauopathy, and mechanisms of neurodegeneration.Laboratory investigation; a journal of technical methods and pathology · 2019
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Cellular factors modulating the mechanism of tau protein aggregation.Cellular and molecular life sciences : CMLS · 2015
    Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Abhinaya IyerNeuroscience Research Institute and Department of Molecular, Cellular and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, United States of America.
Nichole E Lapointe
Krzysztof Zielke
Mariusz Berdynski
Elmer Guzman
Anna Barczak
Małgorzata Chodakowska-Żebrowska
Maria Barcikowska
Stuart Feinstein
Cezary Zekanowski
University of California, Santa Barbara · USMossakowski Medical Research Institute, Polish Academy of Sciences · PLPolish Academy of Sciences · PL

Funding

The Molecular Structure and Function of Tau ProteinR01NS035010 · NINDS · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI FEINSTEIN, STUART C · 1996 to 2010
$2.7M
NINDS NIH HHS NS35010NINDS NIH HHS R01 NS035010
6 · The paper itself

Abstract

Over two dozen mutations in the gene encoding the microtubule associated protein tau cause a variety of neurodegenerative dementias known as tauopathies, including frontotemporal dementia (FTD), PSP, CBD and Pick's disease. The vast majority of these mutations map to the C-terminal region of tau possessing microtubule assembly and microtubule dynamics regulatory activities as well as the ability to promote pathological tau aggregation. Here, we describe a novel and non-conservative tau mutation (G55R) mapping to an alternatively spliced exon encoding part of the N-terminal region of the protein in a patient with the behavioral variant of FTD. Although less well understood than the C-terminal region of tau, the N-terminal region can influence both MT mediated effects as well as tau aggregation. The mutation changes an uncharged glycine to a basic arginine in the midst of a highly conserved and very acidic region. In vitro, 4-repeat G55R tau nucleates microtubule assembly more effectively than wild-type 4-repeat tau; surprisingly, this effect is tau isoform specific and is not observed in a 3-repeat G55R tau versus 3-repeat wild-type tau comparison. In contrast, the G55R mutation has no effect upon the abilities of tau to regulate MT growing and shortening dynamics or to aggregate. Additionally, the mutation has no effect upon kinesin translocation in a microtubule gliding assay. Together, (i) we have identified a novel tau mutation mapping to a mutation deficient region of the protein in a bvFTD patient, and (ii) the G55R mutation affects the ability of tau to nucleate microtubule assembly in vitro in a 4-repeat tau isoform specific manner. This altered capability could markedly affect in vivo microtubule function and neuronal cell biology. We consider G55R to be a candidate mutation for bvFTD since additional criteria required to establish causality are not yet available for assessment.

Indexed as

Amino Acid SequenceFemaleFrontotemporal DementiaHumansMicrotubulesMiddle AgedMolecular Sequence DataMutation, MissensePedigreePolandSequence AlignmentSequence Analysis, DNAtau ProteinsMAPT protein, humantau Proteins

Identifiers

PMID24086739
PMCPMC3785453
OpenAlexW2011236841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.